Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113782 | 1.00 | DRD2 (0.42) | DRD2CACNA1HCD274JAK2JAK1 | |
| SCHEMBL2600821 | 1.00 | DRD2 (0.42) | DRD2CACNA1HCD274JAK2JAK1 | |
| SCHEMBL2112654 | 0.85 | GRIN2B (0.42) | JAK1GRIN2B | |
| SCHEMBL2600817 | 0.85 | GRIN2B (0.42) | JAK1GRIN2B | |
| SCHEMBL2600819 | 0.85 | GRIN2B (0.42) | JAK1GRIN2B | |
| SCHEMBL2600827 | 0.83 | NOS1 (0.51) | DRD2SIGMAR1GRIN2B | |
| SCHEMBL2112633 | 0.83 | DRD2 (0.41) | DRD2CACNA1HCD274JAK2JAK1 | |
| SCHEMBL2600830 | 0.83 | NAMPT (0.40) | JAK2JAK1CCR2GRIN2B | |
| SCHEMBL2113533 | 0.83 | NAMPT (0.40) | JAK2JAK1CCR2GRIN2B | |
| SCHEMBL2600833 | 0.83 | NAMPT (0.40) | JAK2JAK1CCR2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158658-B2 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NORTHWESTERN UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-7994326-B2 | For treatment of various forms of neurodegeneration, including that from stroke, Alzheimer's disease, Parkinson's disease, and Huntington's disease | NORTHWESTERN UNIVERSITY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090104677-A1 | Heteroaromatic Selective Inhibitors of Neuronal Nitric Oxide Synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-23 | — | — | US | disclosed |
| US-7470790-B2 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NORTHWESTERN UNIVERSITY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-08 | — | — | US | disclosed |
| WO-2008042353-A1 | POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NOS1, NOS2, NOS3 | DRD2 1673/4885CACNA1H 2889/4885CD274 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.